Mark Schneyer compensation by year
ACADIA PHARMACEUTICALS Summary Compensation Table · all 5 fiscal years held| Component | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Salary | $398,183 | $467,283 | $484,842 | $518,470 | $546,428 |
| Bonus | $0 | $0 | — | $0 | $0 |
| Stock awards | $2,083,089 | $543,351 | $592,883 | $881,810 | $1,121,727 |
| Option awards | $544,236 | $1,108,825 | $1,176,507 | $843,803 | $1,119,738 |
| Non-equity incentive | $52,337 | $218,515 | $313,494 | $226,719 | $303,341 |
| Pension and deferred compensation | $0 | $0 | — | $0 | $0 |
| All other | $104,973 | $15,230 | $23,478 | $46,711 | $28,174 |
| Total | $3,182,819 | $2,353,204 | $2,591,204 | $2,517,513 | $3,119,408 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ACADIA PHARMACEUTICALS INC DEF 14A filed April 24, 2026, accession 0001193125-26-174163, and prior-year filings. Open the filing on EDGAR.
How this page was built: the ACADIA PHARMACEUTICALS INC filed document, accession 0001193125-26-174163. Every figure is read from that document and cited to the page and table it appears in. Filed April 24, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 69,994 | $1,869,540 | — |
| RSU | 62,738 | $1,675,732 | — |
| RSU | 32,552 | $869,464 | — |
| PSU | 25,692 | $686,233 | — |
| PSU | 19,544 | $522,020 | — |
| RSU | 18,536 | $495,097 | — |
| RSU | 13,630 | $364,057 | — |
| PSU | 6,815 | $182,029 | — |
| PSU | 5,411 | $144,528 | — |
| RSU | 5,276 | $140,922 | — |
| PSU | 5,276 | $140,922 | — |
| Option | 45,318 | — | $17.84 |
Per the Outstanding Equity Awards at Fiscal Year-End table in ACADIA PHARMACEUTICALS INC's FY2025 proxy; value at the fiscal year-end close, as the company printed it. The 12 largest of 15 award rows shown.
Insider transactions since the last proxy
12 Form 4 lines since the FY2025 proxy (filed April 24, 2026)current to 2026-11-10 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-10-30 | Sale | — | 3,321 | $20.88 | 71,322 |
| 2026-10-15 | Grant or award | — | 6,815 | $0.00 | 74,643 |
| 2026-08-06 | Exercise or conversion | 10b5-1 | 14,292 | $17.84 | 82,120 |
| 2026-08-06 | Sale | 10b5-1 | 5,000 | $29.00 | 77,120 |
| 2026-08-06 | Sale | 10b5-1 | 9,292 | $29.34 | 67,828 |
| 2026-08-06 | Exercise or conversion derivative | 10b5-1 | 14,292 | $0.00 | 60,423 |
| 2026-08-05 | Exercise or conversion derivative | 10b5-1 | 5,849 | $0.00 | 74,715 |
| 2026-08-05 | Exercise or conversion | 10b5-1 | 5,849 | $17.84 | 73,677 |
The 8 most recent of 12 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
ACADIA PHARMACEUTICALS’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Catherine Owen Adams | Chief Executive Officer | $8,256,518 |
| Mark Schneyer · this page | Executive Vice President, Chief Financial Officer | $3,119,408 |
| Jennifer Rhodes | Executive Vice President, Chief Legal Officer and Secretary | $2,927,897 |
| Elizabeth Thompson | Executive Vice President, Head of Research and Development | $2,888,383 |
| Thomas Garner | Executive Vice President, Chief Commercial Officer | $857,023 |
Mark Schneyer's compensation dossier, ACADIA PHARMACEUTICALS
You have read Mark Schneyer's totals and holdings. The dossier adds each equity grant ACADIA PHARMACEUTICALS disclosed for Mark Schneyer and ACADIA PHARMACEUTICALS's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full ACADIA PHARMACEUTICALS compensation record
free company briefThis page is one person within ACADIA PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the ACADIA PHARMACEUTICALS proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order ACADIA PHARMACEUTICALS's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ACADIA PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order ACAD
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.